Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Account Payables: 2014-2025

Historic Change in Account Payables for Gyre Therapeutics (GYRE) over the last 10 years, with Sep 2025 value amounting to $483,000.

  • Gyre Therapeutics' Change in Account Payables rose 1625.00% to $483,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $256,000, marking a year-over-year increase of 261.01%. This contributed to the annual value of -$245,000 for FY2024, which is 157.65% down from last year.
  • Gyre Therapeutics' Change in Account Payables amounted to $483,000 in Q3 2025, which was up 1,047.06% from -$51,000 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Change in Account Payables registered a high of $6.3 million during Q4 2022, and its lowest value of -$3.7 million during Q2 2022.
  • For the 3-year period, Gyre Therapeutics' Change in Account Payables averaged around $56,909, with its median value being $3,000 (2023).
  • Per our database at Business Quant, Gyre Therapeutics' Change in Account Payables slumped by 713.11% in 2021 and then skyrocketed by 1,625.00% in 2025.
  • Over the past 5 years, Gyre Therapeutics' Change in Account Payables (Quarterly) stood at $2.6 million in 2021, then soared by 144.48% to $6.3 million in 2022, then slumped by 101.66% to -$104,000 in 2023, then tumbled by 82.69% to -$190,000 in 2024, then surged by 1,625.00% to $483,000 in 2025.
  • Its last three reported values are $483,000 in Q3 2025, -$51,000 for Q2 2025, and $14,000 during Q1 2025.